US FDA tentatively plans December panel review for Contrave anti-obesity agent
This article was originally published in Scrip
Executive Summary
The US FDA has tentatively set aside a date in December for its endocrinologic and metabolic drugs advisory committee to review Orexigen Therapeutics' anti-obesity agent, Contrave (naltrexone SR plus bupropion SR).